TLR9 and neoplasm: Like TLR7/8 agonists, TLR9 agonists and STING agonists delivered IT also promote anti-tumor immunity in mouse models [19, 30], and are currently being investigated in clinical trials (NCT02675439, NCT03172936, NCT02254772).